A combinative effect of low-molecular-weight heparin and intermittent pneumatic compression device for thrombosis prevention during laparoscopic fundoplication.
BACKGROUND. Venous thromboembolism is known to be an important social and health care problem because of its high incidence among patients who undergo surgery. For instance, 20-30% of patients develop this problem after general surgical operations, while 5.5% of patients have this complication when laparoscopic fundoplications are performed without any prophylaxis. The aim of our study was to evaluate the hypocoagulation effect of the following treatments during and after laparoscopic fundoplication: a) intermittent pneumatic compression (IPC) and b) combination of low-molecular-weight heparin (LMWH) and IPC. MATERIAL AND METHODS. The study was performed on 20 consecutive patients who were randomized into two groups. The first group received IPC during operation, the second group received IPC during operation and LMWH before operation. Plasma prothrombin fragment F1+2 (F1+2), thrombin-antithrombin complex (TAT) - markers of thrombogenesis - and plasma free tissue factor pathway inhibitor (fTFPI) - a marker of hypocoagulation effect - were measured 1 h before, during, and after the laparoscopic operation. RESULTS. In the IPC group, plasma F1+2 and TAT levels increased significantly during and after laparoscopic gastrofundoplication. In the IPC+LMWH group, F1+2 and plasma TAT levels did not change during or after the operation. fTFPI levels significantly increased during and after the operation in the IPC+LMWH group; however, fTFPI levels did not change during or after the laparoscopic operation in the IPC group. CONCLUSIONS. A combination of low-molecular-weight heparin and intermittent pneumatic compression during laparoscopic fundoplication caused hypocoagulation effect in the patients, which was not observed in the patients who were treated with intermittent pneumatic compression alone.
Department of Surgery, Kaunas University of Medicine, Kaunas, Lithuania. minkiud@yahoo.com
Mindaugas
M
Kiudelis
Rolandas
R
Gerbutavicius
Rima
R
Gerbutaviciene
Rasa
R
Griniūte
Antanas
A
Mickevicius
Zilvinas
Z
Endzinas
Juozas
J
Pundzius
D000925:Anticoagulants / Q000627:therapeutic use*; D001777:Blood Coagulation; D001779:Blood Coagulation Factors; D003029:Coagulants; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D018662:Fundoplication; D006801:Humans; D007258:Informed Consent; D048228:Intermittent Pneumatic Compression Devices; D007430:Intraoperative Care; D010535:Laparoscopy; D008297:Male; D011182:Postoperative Care; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D013925:Thromboplastin; D020246:Venous Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D003029:Coagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D013925:Thromboplastin